| Drug General Information |
| Drug ID |
D08DVL
|
| Former ID |
DNC013447
|
| Drug Name |
3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H17N5O
|
| Canonical SMILES |
CC1=CC=CC=C1NC2=NC(=NC=C2)NC3=CC=CC(=C3)C(=O)N
|
| InChI |
1S/C18H17N5O/c1-12-5-2-3-8-15(12)22-16-9-10-20-18(23-16)21-14-7-4-6-13(11-14)17(19)24/h2-11H,1H3,(H2,19,24)(H2,20,21,22,23)
|
| InChIKey |
ZUJLZMHZCZZHLN-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Lck tyrosine kinase |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
HTLV-I infection
|
|
Primary immunodeficiency
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Parkinson disease
|
|
T cell activation
|
|
Pathway Interaction Database
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
TCR signaling in naï
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
Regulation of p38-alpha and p38-beta
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
CXCR4-mediated signaling events
|
|
Class I PI3K signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
amb2 Integrin signaling
|
|
EPHA forward signaling
|
|
PDGFR-beta signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Ephrin B reverse signaling
|
|
Alpha-synuclein signaling
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
PECAM1 interactions
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
CD28 co-stimulation
|
|
CD28 dependent PI3K/Akt signaling
|
|
CD28 dependent Vav1 pathway
|
|
CTLA4 inhibitory signaling
|
|
PD-1 signaling
|
|
Interleukin-2 signaling
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
IL-2 Signaling Pathway
|
|
Inflammatory Response Pathway
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Host Interactions of HIV factors
|
|
PIP3 activates AKT signaling
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
TCR signaling
|
|
Costimulation by the CD28 family
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. Epub 2007 Apr 13.N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. |
|---|
